Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.56 |
| ▸ | NISCH | Q9Y2I1 | 4/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.30 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.30 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709618 | 0.89 | GHSR (0.58) | GHSRCYSLTR2CYSLTR1 | |
| SCHEMBL1709676 | 0.86 | GHSR (0.56) | GHSRNISCHCCR4 | |
| SCHEMBL1709668 | 0.82 | GHSR (0.54) | GHSR | |
| SCHEMBL1989435 | 0.81 | GHSR (0.62) | GHSRDUTCCR4 | |
| SCHEMBL1709598 | 0.79 | GHSR (0.58) | GHSR | |
| SCHEMBL1709621 | 0.77 | GHSR (0.56) | GHSRCCR4 | |
| SCHEMBL1709708 | 0.76 | GHSR (0.67) | GHSRCCR4 | |
| SCHEMBL10121926 | 0.76 | GHSR (0.67) | GHSRDUTCCR4 | |
| SCHEMBL10122113 | 0.76 | GHSR (0.56) | GHSRCCR4 | |
| SCHEMBL1991846 | 0.75 | GHSR (0.71) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885NISCH 48/4885ACHE 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.